Table 1.
Patient characteristics at salvage auto-HCT performed with cells procured after previous auto-HCT(s) (* Missing for patients for whom additional data was not obtained).
| Whole population (n = 305) | Patients for whom additional data were obtained (n = 130) | |
|---|---|---|
| Sex | ||
| Male | 207 (68%) | 85 (65%) |
| Female | 98 (32%) | 45 (35%) |
| Year of salvage auto-HCT | ||
| 2000–2004 | 117 (38%) | 18 (14%) |
| 2005–2009 | 29 (10%) | 9 (7%) |
| 2010–2014 | 85 (28%) | 56 (43%) |
| 2015–2018 | 74 (24%) | 47 (36%) |
| Age at salvage auto-HCT; years, median, IQR | 59 (53–63) | 59 (54–65) |
| Age at salvage auto-HCT stratified by the calendar year of salvage auto-HCT; years, median, IQR | ||
| 2000–2004 | 57 (52–62) | 54 (50–60) |
| 2005–2009 | 58 (54–62) | 57 (51–63) |
| 2010–2014 | 60 (56–65) | 60 (56–67) |
| 2015–2018 | 60 (53–66) | 61 (53–66) |
| Number of lines of therapy between previous auto-HCT and salvage auto-HCT | ||
| 1 | 132 (49%) | 67 (53%) |
| 2 | 86 (32%) | 47 (37%) |
| 3 | 35 (13%) | 10 (8%) |
| 4 | 7 (3%) | 1 (1%) |
| ≥5 | 7 (3%) | 1 (1%) |
| Number of lines of therapy between previous auto-HCT and salvage auto-HCT; median, IQR | 2 (1–2) | 1 (1–2) |
| Radiotherapy any time before salvage auto-HCT | 74 (32%) | 40 (41%) |
| Conditioning | ||
| Melphalan only | 292 (96%) | 126 (97%) |
| Melphalan in combination | 12 (4%) | 4 (3%) |
| No melphalan | 1 (0%) | 0 (0%) |
| Stem cell source | ||
| Peripheral blood | 293 (97%) | 127 (99%) |
| Bone marrow | 4 (1%) | 0 (0%) |
| Peripheral blood + bone marrow | 6 (2%) | 1 (1%) |
| Total infused CD34+, x106/kg | ||
| Median, range | 2.92 (1.07–24.5) | 2.74 (1.27–9.42) |
| Missing | 52 (17%) | 19 (15%) |
| Type of cells infused | * | |
| Only new cells | 96 (86%) | 96 (86%) |
| Mixture of old and new cells | 15 (14%) | 15 (14%) |